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Abstract
Patients with alcoholic liver disease frequently exhibit iron over-
load in association with increased hepatic fibrosis. Even moderate
alcohol consumption elevates body iron stores; however, the un-
derlying molecular mechanisms are unknown. Hepcidin, a circu-
latory peptide synthesized in the liver, is a key mediator of iron
metabolism. Ethanol metabolism significantly down-regulated
both in vitro and in vivo hepcidin mRNA and protein expression.
4-Methylpyrazole, a specific inhibitor of the alcohol-metabolizing
enzymes, abolished the effects of ethanol on hepcidin. However,
ethanol did not alter the expression of transferrin receptor1 and
ferritin or the activation of iron regulatory RNa-binding proteins,
IRP1 and IRP2. Mice maintained on 10-20% ethanol for 7 days
displayed down-regulation of liver hepcidin expression without
changes in liver triglycerides or histology. This was accompanied
by elevated duodenal divalent metal transporter1 and ferroportin
protein expression. Injection of hepcidin peptide negated the ef-
fect of ethanol on duodenal iron transporters. Ethanol down-reg-
ulated hepcidin promoter activity and the DNA binding activity of
CCAAT/enhancer-binding protein alpha (C/EBPalpha) but not
beta. Interestingly, the antioxidants vitamin E and N-acetylcyste-
ine abolished both the alcohol-mediated down-regulation of
C/EBPalpha binding activity and hepcidin expression in the liver
and the up-regulation of duodenal divalent metal transporter 1.
Collectively, these findings indicate that alcohol metabolism-me-
diated oxidative stress regulates hepcidin transcription via C/EB-
Palpha, which in turn leads to increased duodenal iron transport.
The antimicrobial peptide hepcidin is producedprimarily by hepatocytes and has key regulatoryroles in iron homeostasis.1 The interaction of
hepcidin with ferroportin, an iron export protein ex-
pressed on the surface of several cell types including en-
terocytes, macrophages, and hepatocytes, facilitates the
internalization and degradation of ferroportin and may
lead to decreased dietary iron absorption and to retention
of iron in body stores.1
Hepcidin expression can be up-regulated by high iron
levels or during acute phase inflammatory responses. In
mice, overexpression of hepcidin produces iron-defi-
ciency anemia whereas hepcidin deficiency manifests as
iron overload.2 Hereditary hemochromatosis is character-
ized by inappropriately low hepcidin expression in the
face of increased body iron stores. Loss-of-function hep-
cidin gene mutations in humans result in severe hemo-
chromatosis phenotypes. Similarly, mutations in genes
encoding HFE, hemojuvelin (HJV), and transferrin re-
ceptor 2 (TFR2) may lead to hemochromatosis via effects
on hepcidin expression.1
Regulation of Hepcidin in Response to Inflamma-
tion. In both Hfe knockout mice and patients with HFE-
related hemochromatosis, most data suggest that
functional HFE is required to maintain basal hepatic hep-
cidin mRNA levels.3 In contrast, the weight of evidence
indicates HFE is not needed for hepcidin up-regulation in
response to inflammation. Lee and colleagues saw in-
creased hepcidin expression in response to lipopolysac-
charide (LPS)-induced inflammation in both Hfe
knockout and wild-type mice.4 Interleukin-6 (IL-6) up-
regulated hepcidin in hepatocytes cultured from either
Hfe knockout or wild-type mice.4 Frazer and colleagues5
reported similar findings and proposed that hepatic hep-
cidin expression is stimulated by an HFE-dependent
mechanism in response to iron but may be overcome in
acute phase inflammatory responses, possibly through a
pathway involving Toll-like receptor 4 (TLR-4) which is
important in the innate immune response. Hepcidin is
up-regulated in iron-deprived wild-type mice injected
with LPS but not in Tlr-4–deficient mice, consistent with
a TLR-4–dependent inflammatory pathway that over-
rides the iron-sensing pathway.6
Consistent with potential roles in hepcidin regulation,
TLR-4 is important in ferroportin down-regulation in
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response to LPS-induced inflammation or exposure to
bacteria.7 In the liver, TLR-4 is involved in Kupffer cell
activation and may be required for hepatic ischemia/
reperfusion injury and hepatic injury following hemor-
rhagic shock, and may contribute to alcoholic liver
disease.8 Regulation of hepatocyte hepcidin expression
through the iron-sensing pathway appears independent of
either Kupffer or peripheral myeloid cells.7,9,10 However
hepcidin regulation through the inflammatory pathway
in response to bacterial pathogens could involve paracrine
effects through Kupffer cells9 or might primarily act
through TLR-4 expressed on peripheral myeloid cells
(macrophages, neutrophils).7
Signaling through TLR-4 activates nuclear factor
B (NF-B), leading to IL-6 production.11 This may
represent one mechanism whereby activation of
Kupffer or other myeloid cells and signaling through
TLR-4 could trigger endocrine responses, altering he-
patic hepcidin expression in liver injury and disease via
TLR-4. Hepcidin is down-regulated in alcoholic liver
injury,12 suggesting it may also be regulated through
TLR-2 or TLR-3, which down-regulates signaling
through TLR-4 to reduce hepatic injury in response to
LPS.13 Although most hepcidin studies used LPS,
which is a model for Gram-negative bacterial infection,
other stimuli trigger different Toll pathways. But if
TLR can regulate hepcidin expression, how does this
interact with the iron sensing pathway?
Regulation of Hepcidin in Response to Iron. Basal
hepcidin gene expression is lower in HFE-related HH or
Hfe knockout mice, although it may be increased above
basal levels in response to altered iron status.3,6,14 The
iron-sensitive mechanism for up-regulating hepcidin ex-
pression in response to iron overload appears to involve
TFR2 and HJV.14-16 Body iron status may be sensed
through diferric transferrin, which has been proposed to
regulate the interactions of HFE with either TFR1 or
TFR2 and subsequent downstream signaling to hepci-
din.17
New insights into the iron-sensing pathway have
emerged from studies by Wang and colleagues18 in mice
with liver-specific disruption of SMAD4, an important
mediator of the transforming growth factor  (TGF-)
super-family signaling pathway. These mice have mark-
edly decreased hepcidin levels and accumulate iron in
liver and other organs and exhibit increased expression of
other iron-related genes including ferroportin, Dcytb and
DMT1. Hepatocyte up-regulation of hepcidin in re-
sponse to both iron and the pro-inflammatory cytokine
IL-6 required SMAD4, suggesting this molecule may be a
nexus between the iron-responsive and the inflammatory
regulatory pathways. Wang and colleagues found hepci-
din was up-regulated by TGF- and another member of
the TGF- super-family, bone morphogenetic protein
(BMP), which both signal through SMAD-dependent
pathways. In each case, up-regulation was abrogated in
SMAD4-deficient hepatocytes.18 Another group failed to
find a TGF- effect but confirmed that BMP can up-
regulate hepatic hepcidin expression through a pathway
likely to involve SMADs.19 This was enhanced by HJV,
proposed to be a BMP co-receptor. HJV belongs to the
repulsive guidance molecule (RGM) family, a subfamily
of the TGF- superfamily, and 2 other RGMs are BMP
co-receptors. A third study showed that regulation of hep-
cidin by BMP2, BMP4, and BMP9 is independent of
HFE, TFR2, and IL-6.20
These observations suggest an integrated mecha-
nism for iron-responsive hepcidin regulation. The in-
volvement of BMPs raises intriguing possibilities for
mechanisms underlying arthritis and osteopenia in
iron overload. Yet much remains to be resolved. The in
vivo data on SMAD phosphorylation, which occurs at
substantial levels even in Hjv/ mice, and the data on
hepcidin expression in hepatocytes from Hjv/ mice
suggest HJV is responsible only for a fraction of the
BMP effect on hepatic hepcidin expression. It is also
not yet clear how the proposed pathway relates other
putative mechanisms for hepcidin regulation through
HJV and TFR2.14 Neogenin, a high-affinity RGM re-
ceptor, may also be a hepatocellular HJV receptor, and
it is possible that different receptor systems may dom-
inate in different in vivo scenarios.21
Coordination of Hepcidin Regulation. Although
the role of HJV needs clarification, we suggest the 2 sides
of the story involving TLR-4 and BMP may be linked
through the protein ECSIT (evolutionarily conserved sig-
naling intermediate in Toll pathways), proposed to medi-
ate cross-talk between the BMP/SMAD and Toll
pathways and apparently essential for SMAD4 transcrip-
tional effects.22,23 Another nexus between the iron and
inflammatory pathways may involve members of the sig-
nal transducer and activator of transcription (STAT) fam-
ily. These are reported to be necessary and sufficient for
IL-6 effects on hepcidin24,25 and probably also contribute
to hepcidin responses to interferon-beta and other cyto-
kines such as leukemia inhibitory factor (LIF) that act
primarily through JAK-STAT mechanisms. There are
various STAT/SMAD interactions.26 The transcriptional
co-activator CBP/p300 forms a physical bridge between
STAT3 and SMAD1, interacting with STAT3 in a cyto-
kine stimulation–independent manner and with SMAD1
in a cytokine stimulation–dependent manner and can
modulate STAT/SMAD interactions.27 A protein inhib-
itor of activated STAT (PIAS) represses BMP signaling
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through SMAD interactions, probably by effects on CBP/
p300.28
The proposed pathways can be broadly summarized as
follows. Iron-related stimuli such as HJV may act through
BMP receptors and possibly also TGF- receptors, both
of which signal through complexes of SMADs that, once
activated, translocate to the nucleus to alter gene expres-
sion. Inflammatory stimuli (e.g., LPS) signal through
Toll-like receptors (TLR), activating kinase pathways that
include cytokine-related signaling factors (e.g., interleu-
kin-1 receptor associated kinase IRAK and tumor necrosis
factor receptor associated factors TRAFs). These path-
ways activate NF-B and c-Jun N-terminal kinase (JNK),
which also translocate to the nucleus. ECSIT is proposed
to interact with TRAF6 and mitogen-activated protein
kinase/extracellular signal regulated kinase kinase 1
(MEKK1) in the cytoplasm and an alternative splice
form, ECSIT2, can localize to the nucleus where it binds
SMADs.19 If ECSIT itself binds cytoplasmic SMADs,
this raises the possibility of bidirectional cross-talk be-
tween the 2 receptor systems. In addition, SMADs may
also cross-talk with JAK-STAT pathways downstream of
cytokine receptors, possibly by CBP/300 family members
physically linking SMADs and STATs, which might be
blocked by PIAS family members. Ultimately, these path-
ways will cause net changes in expression of cytokines,
and probably also other proteins, that in turn regulate
hepcidin gene expression. It is presently unclear as to
whether these systems are in operation in humans. Kemna
and colleagues have now injected LPS into 10 human
volunteers and found increases in IL-6 and urinary hep-
cidin within 6 hours with rapid decreases in serum iron
levels,29 consistent with LPS actions in mice. However,
other studies in humans suggest that inflammation does
not invariably countermand the effects of iron status.
Beutler and colleagues30 postulated that C282Y homozy-
gotes with higher levels of inflammation in general, and
IL-6 in particular, may have greater hepcidin up-regula-
tion, restoring hepcidin to more normal levels and reduc-
ing iron stores in these individuals, contributing to the
variable penetrance of the C282Y mutation. But instead
they found there was no significant relationship between
iron stores (determined by quantitative phlebotomy) and
IL-6 or plasma C-reactive protein, a marker of inflamma-
tion in 19 male and 13 female HFE C282Y homozy-
gotes.30 Another study found liver hepcidin mRNA levels
correlate with iron but not inflammation in hepatitis C
patients.31
In summary, inflammation may not inevitably override
iron signaling in humans. This may partly reflect the stimuli
used because human responses to LPS (modeling inflamma-
tion due to bacterial infection) appear similar to those in
mice while responses to inflammation in hepatitis or hemo-
chromatosis differed from LPS responses in humans or mice.
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